A patient with transthyretin amyloidosis (ATTR) who received the investigational gene therapy nexiguran ziclumeran (nex-z) in ...

Disrupted sleep patterns in Alzheimer’s disease may be more than a symptom—they could be a driving force. Researchers at ...

Intellia Therapeutics (NTLA) stock plummets after the company's Q3 updates indicate a patient deeath in a Phase 3 for its nex ...

Lowering the transcription factor PU.1 reprograms microglia into a neuroprotective, lymphoid-like state that compacts amyloid ...

Shares in gene-editing specialist Intellia Therapeutics came under renewed pressure today after a patient in one of its ...

Microglia (green) responding to aggregated beta-amyloid plaques (blue) in the mouse cortex. (Credit: Jessica M. Crowley) A ...

New diagnostic kits aim to revolutionize early screening of the disease, potentially allowing patients to receive ...

The FDA previously placed two clinical studies on hold, including the Phase III trial in which the liver toxicity occurred.

Awaiting FDA clinical hold letter on MAGNITUDE and MAGNITUDE-2 clinical trials of nex-zPresenting longer-term Phase 1 ...

Intellia Therapeutics has acknowledged the death of the elderly patient hospitalized last week in its Phase III trial of assessing nexiguran ziclumeran (nex-z) in transthyretin amyloidosis with ...